Cocrystal Pharma 2025 net loss narrows as R&D expenses fall

Cocrystal Pharma

31/03/2026 13:11

Overview

US antiviral therapeutics developer's 2025 net loss narrowed yr/yr as R&D expenses declined

Company enrolled first subjects in Phase 1b norovirus challenge study for oral antiviral CDI-988

Cash at year-end fell to $7.7 mln from $9.9 mln a year earlier

Outlook

Company is conducting a Phase 1b norovirus challenge study with CDI-988 at Emory University

Cocrystal plans further development of CDI-988 as a treatment for norovirus and coronaviruses

Company intends to continue development of oral CC-42344 for pandemic and seasonal influenza A

Result Drivers

LOWER R&D SPEND - Co attributed reduced research and development expenses to winddown of Phase 2a influenza study and lower employee-related costs

NOROVIRUS STUDY LAUNCH - Co began Phase 1b norovirus challenge study for oral antiviral candidate CDI-988

LOWER ADMIN COSTS - Co attributed decrease in general and administrative expenses to reduced compensation, insurance and corporate expenses

Company press release: ID:nGNX6NyzbB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$8.83 mln
FY Basic EPS
-$0.78
FY Operating Expenses
$9.02 mln
FY Operating Income
-$9.02 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)